APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neutropenia Biologic Drug Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neutropenia Biologic Drug Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025198 pages

Choose your research edition.

Industry ResearchNeutropenia Biologic Drug Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutropenia Biologic Drug Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neutropenia Biologic Drug Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutropenia Biologic Drug Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutropenia Biologic Drug Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neutropenia Biologic Drug Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neutropenia Biologic Drug Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neutropenia Biologic Drug Treatment include Kyowa Kirin, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis, Pfizer, Baxter International, Amgen, Partner Therapeutics and Myelo Therapeutics GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neutropenia Biologic Drug Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neutropenia Biologic Drug Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neutropenia Biologic Drug Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neutropenia Biologic Drug Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Neutropenia Biologic Drug Treatment Segment by Company

Kyowa Kirin

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis

Pfizer

Baxter International

Amgen

Partner Therapeutics

Myelo Therapeutics GmbH

Enzychem Lifesciences Corporation

Dong-A ST Co.,Ltd.

CVS Health

Cellerant Therapeutics

Neutropenia Biologic Drug Treatment Segment by Type

Filgrastim

Lenograstim

Pegfilgrastim

Sargramostim

Lipegfilgrastim

Neutropenia Biologic Drug Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Neutropenia Biologic Drug Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Biologic Drug Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Biologic Drug Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Biologic Drug Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neutropenia Biologic Drug Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neutropenia Biologic Drug Treatment industry.

Chapter 3: Detailed analysis of Neutropenia Biologic Drug Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neutropenia Biologic Drug Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Filgrastim Table 3. Key Players of Lenograstim Table 4. Key Players of Pegfilgrastim Table 3. Key Players of Sargramostim Table 4. Key Players of Lipegfilgrastim Table 5. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospital Pharmacies Table 7. Key Players of Online Pharmacies Table 8. Key Players of Retail Pharmacies Table 9. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Neutropenia Biologic Drug Treatment Market Share by Region (2021-2026) Table 12. Global Neutropenia Biologic Drug Treatment Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Neutropenia Biologic Drug Treatment Market Share by Region (2027-2032) Table 14. Neutropenia Biologic Drug Treatment Industry Trends Table 15. Neutropenia Biologic Drug Treatment Industry Drivers Table 16. Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges Table 17. Neutropenia Biologic Drug Treatment Industry Restraints Table 18. Global Neutropenia Biologic Drug Treatment Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Company (2021-2026) Table 20. Global Neutropenia Biologic Drug Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Neutropenia Biologic Drug Treatment Key Company Head Office and Area Served Table 22. Global Neutropenia Biologic Drug Treatment Company, Product Type & Application Table 23. Global Neutropenia Biologic Drug Treatment Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Neutropenia Biologic Drug Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Neutropenia Biologic Drug Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Neutropenia Biologic Drug Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2027-2032) Table 36. Kyowa Kirin Company Information Table 37. Kyowa Kirin Business Overview Table 38. Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio Table 40. Kyowa Kirin Recent Development Table 41. Teva Pharmaceutical Industries Ltd. Company Information Table 42. Teva Pharmaceutical Industries Ltd. Business Overview Table 43. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 45. Teva Pharmaceutical Industries Ltd. Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Neutropenia Biologic Drug Treatment Product Portfolio Table 50. Sanofi Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Neutropenia Biologic Drug Treatment Product Portfolio Table 55. Novartis Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Neutropenia Biologic Drug Treatment Product Portfolio Table 60. Pfizer Recent Development Table 61. Baxter International Company Information Table 62. Baxter International Business Overview Table 63. Baxter International Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Baxter International Neutropenia Biologic Drug Treatment Product Portfolio Table 65. Baxter International Recent Development Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Amgen Neutropenia Biologic Drug Treatment Product Portfolio Table 70. Amgen Recent Development Table 71. Partner Therapeutics Company Information Table 72. Partner Therapeutics Business Overview Table 73. Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 75. Partner Therapeutics Recent Development Table 76. Myelo Therapeutics GmbH Company Information Table 77. Myelo Therapeutics GmbH Business Overview Table 78. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio Table 80. Myelo Therapeutics GmbH Recent Development Table 81. Enzychem Lifesciences Corporation Company Information Table 82. Enzychem Lifesciences Corporation Business Overview Table 83. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio Table 85. Enzychem Lifesciences Corporation Recent Development Table 86. Dong-A ST Co.,Ltd. Company Information Table 87. Dong-A ST Co.,Ltd. Business Overview Table 88. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio Table 90. Dong-A ST Co.,Ltd. Recent Development Table 91. CVS Health Company Information Table 92. CVS Health Business Overview Table 93. CVS Health Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. CVS Health Neutropenia Biologic Drug Treatment Product Portfolio Table 95. CVS Health Recent Development Table 96. Cellerant Therapeutics Company Information Table 97. Cellerant Therapeutics Business Overview Table 98. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio Table 100. Cellerant Therapeutics Recent Development Table 101. North America Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 102. North America Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 103. North America Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 104. North America Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 105. North America Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) Table 107. North America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) Table 108. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 109. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 110. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 111. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 112. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) Table 114. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) Table 115. China Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 116. China Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 117. China Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 118. China Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 119. Asia Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 120. Asia Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 121. Asia Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 122. Asia Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 123. Asia Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) Table 125. Asia Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) Table 126. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026) & (US$ Million) Table 127. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032) & (US$ Million) Table 128. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026) & (US$ Million) Table 129. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032) & (US$ Million) Table 130. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026) Table 132. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Neutropenia Biologic Drug Treatment Product Image Figure 2. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neutropenia Biologic Drug Treatment Market Share by Type: 2025 VS 2032 Figure 4. Filgrastim Image Figure 5. Lenograstim Image Figure 6. Pegfilgrastim Image Figure 7. Sargramostim Image Figure 8. Lipegfilgrastim Image Figure 9. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Neutropenia Biologic Drug Treatment Market Share by Application: 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Retail Pharmacies Image Figure 14. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 16. Global Neutropenia Biologic Drug Treatment Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Neutropenia Biologic Drug Treatment Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Neutropenia Biologic Drug Treatment Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Neutropenia Biologic Drug Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2021-2032) Figure 23. Global Neutropenia Biologic Drug Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 26. North America Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032) Figure 27. North America Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032) Figure 28. North America Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 29. United States Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Canada Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 33. Europe Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032) Figure 34. Europe Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032) Figure 35. Europe Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 36. Germany Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 37. France Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 39. Italy Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 40. Russia Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 42. China Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 43. China Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032) Figure 44. China Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032) Figure 45. Asia Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 46. Asia Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032) Figure 47. Asia Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032) Figure 48. Asia Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 49. Japan Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 53. India Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 54. Australia Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032) Figure 59. Brazil Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 64. UAE Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 66. Chile Neutropenia Biologic Drug Treatment Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lenograstim
  • Pegfilgrastim
  • Sargramostim
  • Lipegfilgrastim
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Kyowa Kirin
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis
  • Pfizer
  • Baxter International
  • Amgen
  • Partner Therapeutics
  • Myelo Therapeutics GmbH
  • Enzychem Lifesciences Corporation
  • Dong-A ST Co.,Ltd.
  • CVS Health
  • Cellerant Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Filgrastim
  5. 1.2.3 Lenograstim
  6. 1.2.4 Pegfilgrastim
  7. 1.2.5 Sargramostim
  8. 1.2.6 Lipegfilgrastim
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Retail Pharmacies
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Neutropenia Biologic Drug Treatment Growth Trends by Region
  16. 1.5.1 Global Neutropenia Biologic Drug Treatment Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Neutropenia Biologic Drug Treatment Market Size by Region (2021-2026)
  18. 1.5.3 Neutropenia Biologic Drug Treatment Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Neutropenia Biologic Drug Treatment Market Dynamics
  1. 2.1 Neutropenia Biologic Drug Treatment Industry Trends
  2. 2.2 Neutropenia Biologic Drug Treatment Industry Drivers
  3. 2.3 Neutropenia Biologic Drug Treatment Industry Opportunities and Challenges
  4. 2.4 Neutropenia Biologic Drug Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neutropenia Biologic Drug Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Neutropenia Biologic Drug Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neutropenia Biologic Drug Treatment Key Company Head office and Area Served
  4. 3.4 Global Neutropenia Biologic Drug Treatment Company, Product Type & Application
  5. 3.5 Global Neutropenia Biologic Drug Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neutropenia Biologic Drug Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neutropenia Biologic Drug Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neutropenia Biologic Drug Treatment Tier 1, Tier 2, and Tier 3
4 Neutropenia Biologic Drug Treatment Market by Type
  1. 4.1 Global Neutropenia Biologic Drug Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neutropenia Biologic Drug Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Neutropenia Biologic Drug Treatment Market Size Share by Type (2021-2032)
5 Neutropenia Biologic Drug Treatment Market by Application
  1. 5.1 Global Neutropenia Biologic Drug Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neutropenia Biologic Drug Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Neutropenia Biologic Drug Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Kyowa Kirin
  2. 6.1.1 Kyowa Kirin Company Information
  3. 6.1.2 Kyowa Kirin Business Overview
  4. 6.1.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Kyowa Kirin Neutropenia Biologic Drug Treatment Product Portfolio
  6. 6.1.5 Kyowa Kirin Recent Developments
  7. 6.2 Teva Pharmaceutical Industries Ltd.
  8. 6.2.1 Teva Pharmaceutical Industries Ltd. Company Information
  9. 6.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
  10. 6.2.3 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Teva Pharmaceutical Industries Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  12. 6.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Sanofi Neutropenia Biologic Drug Treatment Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Novartis Neutropenia Biologic Drug Treatment Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Pfizer Neutropenia Biologic Drug Treatment Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Baxter International
  32. 6.6.1 Baxter International Company Information
  33. 6.6.2 Baxter International Business Overview
  34. 6.6.3 Baxter International Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Baxter International Neutropenia Biologic Drug Treatment Product Portfolio
  36. 6.6.5 Baxter International Recent Developments
  37. 6.7 Amgen
  38. 6.7.1 Amgen Company Information
  39. 6.7.2 Amgen Business Overview
  40. 6.7.3 Amgen Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Amgen Neutropenia Biologic Drug Treatment Product Portfolio
  42. 6.7.5 Amgen Recent Developments
  43. 6.8 Partner Therapeutics
  44. 6.8.1 Partner Therapeutics Company Information
  45. 6.8.2 Partner Therapeutics Business Overview
  46. 6.8.3 Partner Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Partner Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  48. 6.8.5 Partner Therapeutics Recent Developments
  49. 6.9 Myelo Therapeutics GmbH
  50. 6.9.1 Myelo Therapeutics GmbH Company Information
  51. 6.9.2 Myelo Therapeutics GmbH Business Overview
  52. 6.9.3 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Myelo Therapeutics GmbH Neutropenia Biologic Drug Treatment Product Portfolio
  54. 6.9.5 Myelo Therapeutics GmbH Recent Developments
  55. 6.10 Enzychem Lifesciences Corporation
  56. 6.10.1 Enzychem Lifesciences Corporation Company Information
  57. 6.10.2 Enzychem Lifesciences Corporation Business Overview
  58. 6.10.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product Portfolio
  60. 6.10.5 Enzychem Lifesciences Corporation Recent Developments
  61. 6.11 Dong-A ST Co.,Ltd.
  62. 6.11.1 Dong-A ST Co.,Ltd. Company Information
  63. 6.11.2 Dong-A ST Co.,Ltd. Business Overview
  64. 6.11.3 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Dong-A ST Co.,Ltd. Neutropenia Biologic Drug Treatment Product Portfolio
  66. 6.11.5 Dong-A ST Co.,Ltd. Recent Developments
  67. 6.12 CVS Health
  68. 6.12.1 CVS Health Company Information
  69. 6.12.2 CVS Health Business Overview
  70. 6.12.3 CVS Health Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 CVS Health Neutropenia Biologic Drug Treatment Product Portfolio
  72. 6.12.5 CVS Health Recent Developments
  73. 6.13 Cellerant Therapeutics
  74. 6.13.1 Cellerant Therapeutics Company Information
  75. 6.13.2 Cellerant Therapeutics Business Overview
  76. 6.13.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product Portfolio
  78. 6.13.5 Cellerant Therapeutics Recent Developments
7 North America
  1. 7.1 North America Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 7.2 North America Neutropenia Biologic Drug Treatment Market Size by Type
  3. 7.2.1 North America Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Neutropenia Biologic Drug Treatment Market Size by Application
  7. 7.3.1 North America Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Neutropenia Biologic Drug Treatment Market Size by Country
  11. 7.4.1 North America Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 8.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type
  3. 8.2.1 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Neutropenia Biologic Drug Treatment Market Size by Application
  7. 8.3.1 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country
  11. 8.4.1 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 9.2 China Neutropenia Biologic Drug Treatment Market Size by Type
  3. 9.2.1 China Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032)
  6. 9.3 China Neutropenia Biologic Drug Treatment Market Size by Application
  7. 9.3.1 China Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 10.2 Asia Neutropenia Biologic Drug Treatment Market Size by Type
  3. 10.2.1 Asia Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Neutropenia Biologic Drug Treatment Market Size by Application
  7. 10.3.1 Asia Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Neutropenia Biologic Drug Treatment Market Size by Country
  11. 10.4.1 Asia Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst